PARABILIS MEDICINES ANNOUNCES OVERSUBSCRIBED $305 MILLION FINANCING TO SUPPORT ONGOING FOG-001 (ZOLUCATETIDE) CLINICAL DEVELOPMENT ACROSS A BROAD RANGE OF TUMORS AND ADVANCE PIONEERING PIPELINE AND HELICON PLATFORM

Reuters · 5d ago

Please log in to view news